



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Ankleshwar – 393002,
Gujarat, India
Tel : 91-7045456789 / 7046456789
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400058, India.
Tel : (91-22) 26701050 / 1 / 2 / 3
Email: contact@samratpharmachem.in

May 30, 2022

To,
Department of Corporate Services,
BSE Limited
P J Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 530125

Dear Sir,

Sub: Outcome of the Board Meeting of the Company held today

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, May 30, 2022, the Board has considered and adopted the attached Audited Financial Results of the Company for the year ended March 31, 2022, which is enclosed herewith along with the Statement of Assets and Liabilities, Cash Flow Statement, Auditor's Report and Declaration for Unmodified Opinion on the Financial Results of the Company.

The meeting of the Board of Directors of the Company commenced at 14:00 hrs and concluded at 16:00 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully,
For Samrat Pharmachem Limited

Nishant Kankaria
Company Secretary & Compliance Officer



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat (Website: www.samratpharmachem.com)

Corp Office : 701/702 Business Square, M. A. Road, Andheri (West), Mumbai - 400 058 (CIN: L24230GJ1992PLC017820)

(Rs. in Lakhs)					
Statement of Standalone Audited Results for the Quarter and for the Year Ended 31 MARCH, 2022					
Particulars	Quarter Ended			Year Ended	
	31-Mar-22 (Audited)	31-Dec-21 (Unaudited)	31-Mar-21 (Audited)	31-Mar-22 (Audited)	31-Mar-21 (Audited)
1 (a). Revenue from Operations	6,015.78	5,534.39	4,741.26	22,181.17	17,901.78
(b). Other Income	8.61	23.42	32.12	55.08	46.28
Total Revenue	6,024.39	5,557.81	4,773.38	22,236.25	17,948.06
2. Expenses					
a) Cost of materials consumed	4,891.76	4,422.04	4,291.36	19,023.42	16,201.76
b) Purchase of Traded Goods	0.00	0.00	0.00	0.00	0.00
c) Changes in inventories of FG, WIP & Stock in trade	-114.46	29.50	64.01	-33.33	222.75
d) Employee Costs	52.75	46.86	44.27	177.47	149.80
e) Finance Cost	16.82	12.55	17.48	67.45	127.67
f) Depreciation & Amortisation expense	15.08	15.14	13.47	59.47	49.29
g) Other Expenses	168.79	175.81	146.99	579.28	460.64
(i) Manufacturing Expenses	101.02	109.72	78.84	376.66	286.50
(ii) Administration Expenses	34.44	26.46	26.01	93.35	72.44
(iii) Selling & Distribution Expenses	33.33	39.63	42.14	109.27	101.70
Total Expenses	5,030.74	4,701.90	4,577.58	19,873.76	17,211.91
3. Profit before exceptional items and tax	993.65	855.91	195.80	2,362.49	736.15
4. Exceptional Items	-2.34	0.00	-1.77	-2.34	-1.77
5. Profit before extraordinary items & tax	991.31	855.91	194.03	2,360.15	734.38
6. Extraordinary items	0.00	0.00	0.00	0.00	0.00
5. Profit before tax	991.31	855.91	194.03	2,360.15	734.38
6. Tax expense					
a) Current Tax	-302.99	-211.58	-41.65	-638.82	-172.29
b) Deferred Tax	11.15	0.36	3.59	-2.84	-28.78
Total Tax Expense	-291.84	-211.22	-38.06	-641.66	-201.07
7. Profit (Loss) for the period from continuing operations	699.47	644.69	155.97	1,718.49	533.31
8. Profit / (Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
9. Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
10. Profit / (Loss) from discontinuing operations after tax	0.00	0.00	0.00	0.00	0.00
11. Profit / (Loss) for the period	699.47	644.69	155.97	1,718.49	533.31
12. Other Comprehensive Income (OCI)	0.00	0.00	0.00	0.00	0.00
13. Total Comprehensive Income for the period	699.47	644.69	155.97	1,718.49	533.31
14. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97	308.97
15. Earnings per equity share (not annualized)					
a) Basic	22.64	20.87	5.05	55.62	17.26
b) Diluted	22.64	20.87	5.05	55.62	17.26



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Standalone Statement of Assets and Liabilities		(Rs. in Lakhs)	
Particulars	As at 31-Mar-22 (Audited)	As at 31-Mar-21 (Audited)	
ASSETS			
Non-Current Assets			
Property, Plant and Equipment	997.72	939.39	
Capital work-in-progress	0.00	0.00	
Intangible assets	0.85	0.94	
Intangible assets under development	0.00	0.00	
Financial Assets			
Investments	0.00	0.00	
Loans	20.57	20.47	
Deferred tax assets (net)	0.00	0.00	
Other non-current assets	59.70	46.46	
Total Non Current Assets	1,078.84	1,007.26	
Current Assets			
Inventories	1,241.60	1,139.99	
Financial Assets			
Investments	1.00	0.10	
Trade Receivables	4,357.46	3,300.54	
Cash and Cash Equivalents	1,726.75	250.59	
Loans	1.50	1.80	
Other Financial Assets	0.00	0.00	
Other current assets	54.05	39.37	
Total Current Assets	7,382.36	4,732.39	
Total Assets	8,461.20	5,739.65	
EQUITY AND LIABILITIES			
Equity			
Equity Share capital	308.97	308.97	
Other Equity	4,373.20	2,654.72	
Total Equity	4,682.17	2,963.69	
Non-Current Liabilities			
Financial Liabilities			
Borrowings	0.00	0.00	
Provisions	0.00	0.00	
Deferred Tax Liabilities (Net)	46.09	43.26	
Other Non-Current Liabilities	0.00	0.00	
Total Non-Current liabilities	46.09	43.26	
Current Liabilities			
Financial Liabilities			
Borrowings	751.97	879.37	
Trade Payables	2,334.11	1,766.01	
Other Financial Liabilities	0.00	0.00	
Other Current Liabilities	87.72	17.09	
Provisions	559.14	70.23	
Total Current Liabilities	3,732.94	2,732.70	
Total Liabilities	8,461.20	5,739.65	



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Notes

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The above results have been taken on record by the Board of Directors at its Meeting held on Monday, 30 May 2022 at the Corporate Office of the Company.
3. The figures of the quarter ended 31 Mar 2022 and 31 Mar 2021 are the balancing figures between the audited figures in respect of full financial years and the published (unaudited) up to the third quarter of relevant financial year.
4. The Board of Directors has recommended dividend of Re. 1/- per fully paid equity share of Rs. 10/- each (10%) for the financial year ended 31 March, 2022, subject to approval of the members at the ensuing Annual General Meeting of the Company.
5. The Company manufactures pharmaceutical chemicals, which is a single business segment.
6. The figures for the previous period have been regrouped where necessary to conform to current period's classification.

**By order of the Board of Directors
For Samrat Pharmachem Limited**

Place : Mumbai
Date : 30 May 2022

Rajesh Mehta
Executive Director



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH, 2022

Particulars	31-Mar-22 Rs. Lakhs	31-Mar-21 Rs. Lakhs
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit Before Tax And Extraordinary Items	2,360.14	734.39
Adjustments For :		
Depreciation	59.47	49.29
Profit/Loss On Sale Of Assets	2.34	1.77
Profit/Loss On Sale Of Investments	-0.75	0.00
Finance Cost	67.45	127.67
Bad Debts, Reserve For Doubtful Debts & Discount	3.96	-0.14
Interest/Dividend Income	-13.86	-8.55
	118.61	170.04
Operating Profit Before Working Capital Changes	2,478.75	904.43
Adjustments For :		
Trade Receivables	-1,056.92	-519.26
Other Receivables	-30.84	126.14
Inventories	-101.61	736.75
Trade And Other Payables	642.27	-542.86
	-547.10	-199.23
Cash Generated From Operations	1,931.65	705.19
Direct Taxes Paid	-153.46	-225.43
	-153.46	-225.43
Cash Flow Before Extraordinary Items	1,778.19	479.76
Extraordinary Items		
Net Cash From Operating Activities	1,778.19	479.76
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase Of Fixed Assets	-127.63	-272.86
Sale/Realization Of Fixed Assets	7.58	0.00
Capital Work-In-Progress	0.00	108.08
Addition/Realization Of Investments/FDR	-30.15	-134.95
Interest/Dividend Received	13.02	7.39
Net Cash Used In Investing Activities	-137.17	-292.34
	Continued ...	



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Particulars	31-Mar-22 Rs. Lakhs	31-Mar-21 Rs. Lakhs
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds From Issue Of Share Capital	0.00	0.00
Interest & Finance Charges Paid	-67.45	-127.46
Proceeds/Repayment - Long Term Borrowings	0.00	-31.21
Proceeds/Repayment - Short Term Borrowings	-127.40	-30.30
Net Cash Used In Financing Activities	-194.84	-188.97
 NET INCREASE IN CASH AND CASH EQUIVALENTS	 1,446.17	 -1.56
CASH AND CASH EQUIVALENTS AT 1/Apr (Opening Balance)	24.18	25.74
CASH AND CASH EQUIVALENTS AT 31/Mar (Closing Balance)	1,470.35	24.18

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

For Samrat Pharmachem Limited

Rajesh Mehta
Executive Director
[DIN: 00216731]

Place : Mumbai
Date : 30 May 2022



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Ankleshwar – 393002,
Gujarat, India
Tel : 91-7045456789 / 7046456789
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400058, India.
Tel : (91-22) 26701050 / 1 / 2 / 3
Email: contact@samratpharmachem.in

May 30, 2022

To,
**Department of Corporate Services,
BSE Limited**
P J Towers,
Dalal Street,
Mumbai - 400 001.

Sub: Declaration with respect to Audit report with unmodified opinion for the financial year ended March 31, 2022

Dear Sir,

Pursuant to clause 4.1 of SEBI circular no CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that the Statutory Auditors of the company M/s Shah & Savla LLP, Chartered Accountants, Mumbai, have issued the audit report under the Companies Act 2013 on the Standalone Financial Results of the Company as prepared under SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015 for the financial year ended March 31, 2022, with unmodified opinion.

Request to take note of the above

Thanking You.

Yours faithfully,
For Samrat Pharmachem Limited

Nishant Kankaria
Company Secretary & Compliance Officer



Independent Auditor's Report on the Quarterly and Year to Date Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**To the Board of Directors of,
Samrat Pharmachem Limited**

Report on the audit of the Financial Results

Opinion

We have audited the accompanying statement of quarterly (refer 'Other Matters' section below) and year to date financial results of Samrat Pharmachem Limited ('the Company') for the quarter and year ended March 31, 2022 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- is presented in accordance with the requirements of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibility for the Financial Results

The statement has been prepared on the basis of the Annual Financial Statements. The Board of Directors of the company are responsible for the preparation and presentation of the Statement that

gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view & are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists

related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2022 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For Shah & Savla LLP
Chartered Accountants
FRN :109364W/W100143

CA. Mulesh M. Savla
(Partner)
Membership No. 038404

Place: Mumbai
Date : 30th May, 2022